Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant MutationsTed W. Johnson, Martin P. Edwards, Jacqui Hoffman et al.|Journal of Medicinal Chemistry|2014Cited by 587
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)Pei‐Pei Kung, Martin P. Edwards, Patrick Bingham et al.|Journal of Medicinal Chemistry|2017Cited by 128
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to CrizotinibQinhua Huang, Martin P. Edwards, Ted W. Johnson et al.|Journal of Medicinal Chemistry|2014Cited by 118
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)Hengmiao Cheng, John C. Kath, Suvi T. M. Orr et al.|Journal of Medicinal Chemistry|2020Cited by 40
CCDC 986729: Experimental Crystal Structure DeterminationTed W. Johnson, Martin P. Edwards, Paul Richardson et al.|The Cambridge Structural Database|2014Cited by 0